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ABSTRACT
Background and Objectives: Guidelines recommend either EUS or magnetic resonance cholangiopancreatography (MRCP)
for intermediate risk of choledocholithiasis. There is a lack of evidence that supports proceeding with EUS if the MRCP is
negative and if clinical suspicion still exists. Methods: This is a retrospective study of all patients who underwent EUS to
assess for choledocholithiasis at a tertiary care referral center from July 2013 to October 2019. Results: A total of 593 patients
underwent EUS for evaluation for choledocholithiasis. Of the 593 patients, 35.2% (209/593) had an MRCP. 73.2% (153/209)
had a negative MRCP while 26.8% (56/209) had a positive MRCP. Of the group of patients who underwent EUS with a
negative MRCP, 15% (23/153) were positive for choledocholithiasis on EUS. Of these, 91% (21/23) were also positive for
sludge or stones on endoscopic retrograde cholangiopancreatography and thus 14% (21/153) of the EUS were “true positives.”
There were no clinical or laboratory factors predictive of choledocholithiasis on univariate analysis in the EUS plus negative
MRCP group. When further analyzing the MRCP negative group into MRCP‑/EUS+ and MRCP‑/EUS‑subgroups, a total
bilirubin >3 mg/dL predicted a bile duct stone (55% vs. 32%, P = 0.05). Conclusion: The diagnostic yield of EUS for
suspected choledocholithiasis in the setting of a negative MRCP is 14% in our cohort. EUS should be considered in patients
with intermediate risk of choledocholithiasis with a negative MRCP if the clinical suspicion is still present, and especially
if the total bilirubin is above 3 mg/dL.
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INTRODUCTION
Gallstone disease can affect up to 15% of the
population in the United States and is one of the
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leading causes of hospital admissions.[1] The annual
cost of gallstone disease is over 6.6 billion dollars.[2]
Up to 20% of patients with cholelithiasis can develop
choledocholithiasis.[3] According to the American Society
of Gastrointestinal Endoscopy (ASGE) and European
Society of Gastrointestinal Endoscopy (ESGE), those
who have high‑risk criteria for choledocholithiasis
should proceed directly to ERCP. [4,5] These criteria
include choledocholithiasis seen on imaging, an total
bilirubin >4 mg/dL and with a dilated bile duct, and
ascending cholangitis. Low risk for choledocholithiasis
is the presence of normal liver function tests and
normal abdominal ultrasound.[5] No further workup
is needed for low‑risk patients. Intermediate risk is
defined as abnormal liver function tests or dilated
bile duct on ultrasound. [4,5] In this scenario, it is
recommended to undergo EUS or magnetic resonance
cholangiopancreatography (MRCP) for further diagnostic
evaluation.
In 2015, a Cochrane review compared the
diagnostic accuracy of EUS to MRCP for suspected
choledocholithiasis. [6] The comprehensive review
concluded that both EUS and MRCP have high
diagnostic accuracy for detection of common bile duct
(CBD) stones and thus those who have a negative
EUS or MRCP do not need further invasive workup.
It does stipulate, however, that if symptoms persist,
further investigation is indicated. In our clinical
practice, we will occasionally consult on patients with
intermediate risk for CBD stones with abdominal pain
in the setting of a negative MRCP. In this situation
we consider performing an EUS, and we have found
positive results on EUS that then lead to therapeutic
ERCP [Figure 1] and resolution of symptoms. However
to our knowledge there is no literature on the yield of
EUS when an MRCP is negative. This study aimed to
evaluate the diagnostic yield of EUS in this clinical
situation.

a

b

METHODS
This is a retrospective study of all patients who
underwent EUS to assess for CBD stones at a tertiary
care referral center from July 2013 to October 2019.
All procedures were standard of care, in accordance
with the ethical standards of the responsible committee
on human experimentation, and with the Helsinki
Declaration of 1975, as revised in 2000. Institutional
review board approval was granted for this study. The
primary aim of this study was to report our diagnostic
yield for choledocholithiasis found by EUS in patients
with intermediate risk of choledocholithiasis who
underwent a negative MRCP and subsequent EUS for
continued suspicion of a bile duct stone based on one
of the following: Continued abdominal pain and/or
abnormal Liver enzymes. Secondary outcomes were
to determine if there were any clinical or laboratory
predictors that would predict a positive EUS in the
setting of a negative MRI.
Inclusion criteria included: (1) patients with intermediate
risk for choledocholithiasis undergoing an EUS
procedure with or without a prior MRI/MRCP.
Inter mediate risk was defined as per the ASGE
guidelines as presence of a dilated bile duct >6
mm or a bilirubin 1.8 mg/dL ‑ 4.0 in the absence
of a stone seen on imaging, cholangitis, or a total
bilirubin >4.0 mg/dL in patients with right upper
quadrant (RUQ) pain or clinical gallstone pancreatitis[4]
(2) age >18 years old. EUS data was abstracted from a
prospectively maintained endoscopy database and clinical
characteristics, laboratory values, and radiology reports
were obtained from the corresponding electronic charts
of patients who met inclusion criteria. Covariates
of interest included demographic characteristics, lab
parameters, and clinical parameters. Demographic
characteristics included age (years) and gender (female,
male). Lab parameters included white blood cell
count (<10.5 × 10 9/L, ≥10.5 × 10 9/L), aspartate

c

Figure 1. An example from a patient in this study showing (a) a negative magnetic resonance cholangiopancreatography (b) a subsequent EUS
showing a bile duct stone (yellow arrow), and (c) a bile duct stone being removed on ERCP
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aminotransferase (≤40 U/L, >40 U/L), alanine
aminotransferase, (≤41 U/L, >40 U/L), alkaline
phosphatase (≤120 U/L, >120 U/L), and total bilirubin
(≤3 mg/dL, >3 mg/dL). Clinical parameters included
RUQ pain (yes, no), fever (yes, no), acute pancreatitis
(yes, no), and bacteremia (yes, no).
All EUS procedures were performed using a curved
linear array echoendoscope (GF‑UCT180, Olympus
America, Center Valley, PA, USA) attached to an
ultrasound system (Prosound F75 Processor, Hitachi
Healthcare Americas, Twinsburg, OH, USA). If the EUS
was positive for choledocholithiasis (round hyperechoic
object with shadowing) it was then followed by an
ERCP. The standard of care for choledocholithiasis in
our health system, is to perform an ERCP regardless
of the bile duct size; as intraoperative cholangiogram
is not guaranteed to remove the stone. In addition,
intra‑operative cholangiogram is not routinely performed
on every patient undergoing cholecystectomy, and is
performed at the discretion of the surgeon. A “true
positive” EUS was defined by a positive EUS plus a
stone or obvious visible sludge removed on ERCP.
Thus, ERCP was considered the gold standard for the
diagnosis of choledocholithiasis. Stone size was not
routinely measured on EUS or ERCP as it did not
impact clinical decision‑making or care. All patients that
had a positive EUS and negative MRCP had the MRCP
re‑reviewed by an experienced gastrointestinal radiologist
to confirm the MRCP was truly negative. This was
done to mitigate the potential bias of a false negative
MRCP that can occur due to the inherently imperfect
interobserver agreement of radiology studies.[7,8]
For data analysis, patients included in the study were
stratified into three subgroups: EUS plus no MRCP,
EUS plus negative MRCP, and EUS plus positive
MRCP (EUS performed just prior to ERCP to confirm
the stone was still present in the bile duct and did
not pass). Baseline characteristics, lab parameters,
and clinical parameters were described for the entire
study population and compared across subgroups.
The continuous variables were described using means
and standard deviations or medians and interquartile
ranges. Categorical variables were described using
frequencies and percentages. Significant differences
between subgroups were evaluated with the Chi‑square
test, Fisher’s exact test, one‑way ANOVA test, or
two‑sample t‑test, as appropriate. A log transformation
was used to normalize the distribution of time from
MRCP to EUS/ERCP prior to analysis.

The MRCP performed and negative subgroup was
further stratified into EUS positive and EUS negative.
Demographic characteristics, lab parameters, and clinical
parameters were compared between MRCP−/EUS+ and
MRCP−/EUS− subgroups as well as between MRCP−/
EUS+ and no MRCP. The continuous variable was
summarized using mean and standard deviation, and
a two‑sample t‑test was used to test for a significant
difference across subgroups. Categorical variables were
summarized using frequency and percent, and the
Chi‑square test or Fisher’s exact test was used to test
for any significant differences across MRCP groups, as
appropriate.
For each subgroup, univariable analysis for
bivariate associations between each covariate and
choledocholithiasis (diagnosed by gold standard ERCP)
was performed using logistic regression. For the subgroup
“EUS plus no MRCP,” there were sufficient patients
to conduct a multivariable analysis to determine the
independent effect of covariates using multivariable logistic
regression. Variables were included in the multivariable
regression if they were found to have a significant
univariable association. A relaxed P < 0.10 was used for
inclusion in the multivariable model to avoid excluding
important variables. For the subgroups “EUS plus negative
MRCP” and “EUS plus positive MRCP” there were
insufficient patients to conduct multivariable analyses.
Sensitivity analyses were performed to assess the
importance of missing lab parameter data. The first
sensitivity analysis was conducted by substituting a
“normal” lab value range for all participants with
missing data, and the second sensitivity analysis was
conducted by substituting an “non‑normal” lab value
for all participants with missing data. Both sensitivity
analyses included 573 patients. All analyses were
performed using SAS Studio version 3.8, SAS, Cary,
North Carolina, USA with P < 0.05 considered
significant unless otherwise noted.
RESULTS
A total of 593 patients underwent an EUS to evaluate
for choledocholithiasis. Figure 2 is a flowchart of
patients included in this study. Of the 593 patients,
64.7% (384/593) did not have an MRCP. In this
subgroup “EUS plus no MRCP,” 34% (132/384)
had an EUS positive for choledocholithiasis of
which 97% (128/132) was confir med on ERCP.
Thus, 33% (128/384) of these patients had a “true
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TOTAL EUS
Performed
n = 2772

EUS looking for
CBD stone
n = 593

MRCP
Not performed
n = 384

EUS
Positive
% positive = 34.38%
n = 132

ERCP
Positive
n = 128

EUS
Negative
% negative = 65.63%
n = 252

ERCP
Negative
n=4

MRCP
Negative
n = 153

EUS
Positive
% positive = 15.03%
n = 23

ERCP
Positive
n = 21

MRCP
Positive
n = 56

EUS
Negative
% negative = 84.97%
n = 130

ERCP
Negative
n=2

EUS
Positive
% positive = 75%
n = 42

ERCP
Positive
n = 42

EUS
Negative
% negative = 25%
n = 14

ERCP
Negative
n=0

Figure 2. A flowchart of patients included in this study. MRCP: magnetic resonance cholangiopancreatography

positive” EUS. 35.2% of the patients (209/593) had
a MRCP; 73.2% (153/209) had a negative MRCP
while 26.8% (56/209) had a positive MRCP. Of
the patients in the subgroup “EUS plus negative
MRCP,” 15% (23/153) had a EUS positive for
choledocholithiasis while 85% (130/153) had a
negative EUS. Of the patients with positive EUS
in this subgroup, 91% (21/23) were confir med
positive on ERCP and thus 14% (21/153) had a
“true positive” EUS. The 56 patients in the subgroup
“EUS plus positive MRCP” had an EUS performed
to confirm choledocholithiasis prior to ERCP. Of
these patients, 75% (42/56) were positive for a stone
on EUS. The ERCP that followed was positive for
a stone in all 42 cases (75% (42/56) “true positive”
EUS rate). The patients that tested negative for
a stone on EUS (25%, 14/56) did not undergo
subsequent ERCP.
Of the 593 patients analyzed for the primary outcome,
503 patients could be analyzed for the secondary
outcome; to discover clinical or laboratory predictors
that predict a “true positive” EUS in the setting of a
negative MRCP. 90 patients were not included because
they had missing data for at least one clinical or
340

laboratory parameter. Table 1 shows the clinical and
laboratory data in each of the three subgroups.
Table 2 shows the main secondary outcome of interest,
the univariate analysis evaluating whether there are
any clinical or laboratory parameters that predict a
“true positive” EUS for choledocholithiasis in patients
that had a negative MRCP. We show here that there
are no statistically significant associations that predict
choledocholithiasis in this group. When further analyzing
the MRCP negative group into MRCP−/EUS+ and
MRCP−/EUS− subgroups, a total bilirubin >3 mg/dL
predicted a bile duct stone [Table 3].
Among patients who did not have a MRCP and went
straight to EUS+/−ERCP, univariate and multivariate
analysis [Table 4] showed that alkaline phosphatase
>120 U/L (odds ratio [OR] 2.39 P = 0.0065), RUQ
pain (OR 3.22, P = 0.0008), and acute pancreatitis
(OR 0.5, P = 0.028) all predict choledocholithiasis
found on both EUS and ERCP.
There were 21 patients who had negative MRCPs
but had “true positive” EUS. These MRCPs were
re‑reviewed by a senior GI radiologist. Both radial
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Table 1. Differences in demographic characteristics, lab parameters, and clinical parameters across
subgroups
Baseline characteristics
Age (years), mean (SD)
Gender
Female
Male
Cholecystectomy status
No
Yes
Lab parameters
WBC
<10.5×109/L
≥10.5×109/L
AST
≤40 U/L
>40 U/L
ALT
≤41 U/L
>41 U/L
Alkaline phosphatase
≤120 U/L
>120 U/L
Total bilirubin
≤3 mg/dL
>3 mg/dL
Clinical parameters
RUQ pain
No
Yes
Fever
No
Yes
Acute pancreatitis
No
Yes
Bacteremia
No
Yes
Time from MRCP to EUS/ERCP (h)
Median (Q1–Q3)

EUS plus no MRCP
(n=328), n (%)

EUS plus negative MRCP
(n=124), n (%)

EUS plus positive MRCP
(n=54), n (%)

P

54.45 (18.77)

52.77 (18.17)

54.59 (21.62)

0.68

207 (63.11)
121 (36.89)

76 (61.29)
48 (38.71)

44 (81.48)
10 (18.52)

0.02

254 (77.44)
74 (22.56)

85 (68.55)
39 (31.45)

45 (83.33)
9 (16.67)

0.06

236 (71.95)
92 (28.05)

96 (77.42)
28 (22.58)

44 (81.48)
10 (18.52)

0.22

108 (32.93)
220 (67.07)

34 (27.42)
90 (72.58)

15 (27.78)
39 (72.22)

0.46

94 (28.66)
234 (71.34)

35 (28.23)
89 (71.77)

13 (24.07)
41 (75.93)

0.79

139 (42.38)
189 (57.62)

38 (30.65)
86 (69.35)

15 (27.78)
39 (72.22)

0.02

241 (73.48)
87 (26.52)

80 (64.52)
44 (35.48)

41 (75.93)
13 (24.07)

0.13

79 (24.09)
249 (75.91)

39 (31.45)
85 (68.55)

14 (25.93)
40 (74.07)

0.28

294 (89.63)
34 (10.37)

106 (85.48)
18 (14.52)

51 (94.44)
3 (5.56)

0.19

248 (75.61)
80 (24.39)

101 (81.45)
23 (18.55)

50 (92.59)
4 (7.41)

0.013

317 (96.65)
11 (3.35)

120 (96.77)
4 (3.23)

52 (96.30)
2 (3.70)

1.00

NA

54.92 (25.82–217.23)

54.06 (26.38–163.28)

0.9973

OR: Odds ratio; CI: Confidence interval; WBC: White blood cell count; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; RUQ: Right upper
quadrant; MRCP: Magnetic resonance cholangiopancreatography

MRCP and 3D respiratory‑triggered images were
reviewed. Of the MRCP studies, 90% (19/21) were
determined to be negative for choledocholithiasis.
The bile duct size was measured in these cases and
the median bile duct size was 7 mm with a range of
5–14 mm.
DISCUSSION
To our knowledge, this is the first study to examine the
diagnostic yield of EUS when the MRCP is negative

for choledocholithiasis. A few studies studies have
showed the benefit of EUS after a negative computed
tomography (CT) scan. In a study of 156 patients,
EUS showed a 34% (53/156) yield when the CT
scan was negative. [9] Another study showed a 28%
yield of choledocholithiasis in 72 patients whose CT
scans were negative. The sensitivity and specificity for
choledocholithiasis in this cohort was 87% and 100%
respectively.[10] A third study retrospectively evaluated
200 patients with intermediate or high probability for
choledocholithiasis and negative CT scans. [11] EUS
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Table 2. Univariable association between
covariates and “true positive” EUS for
choledocholithiasis among those with negative
magnetic resonance cholangiopancreatography
(n=124)
Variable

Univariable OR
(95% CI)

Age
Sex (male vs. female)
WBC (≥10.5×109/L vs. <10.5×109/L)
AST (>40 U/L vs. ≤40 U/L)
ALT (>41 U/L vs. ≤41)
Alkaline phosphatase (>120
U/L vs. ≤120 U/L)
Total bilirubin (>3 mg/dL vs. ≤3 mg/dL)
RUQ pain (yes vs. no)
Fever (yes vs. no)
Acute pancreatitis (yes vs. no)
Bacteremia (yes vs. no)

1.00
1.01
0.17
0.98
1.03
2.47

P

(0.97–1.03)
(0.36–2.81)
(0.02–1.36)
(0.32–2.99)
(0.34–3.13)
(0.67–9.08)

0.9238
0.9865
0.0947
0.9705
0.9637
0.1751

2.03 (0.74–5.56)
2.57 (0.70–9.46)
0.31 (0.04–2.47)
0.51 (0.11–2.37)
0.62 (0.02–16.76)

0.1693
0.1555
0.2676
0.3876
0.7737

*Firth logistic regression used to address quasi-complete separation of
data. OR: Odds ratio; CI: Confidence interval; WBC: White blood cell
count; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase;
RUQ: Right upper quadrant

diagnosed a stone in 165/200 patients (83%) and
161 (81%) were confirmed on ERCP. EUS had an
accuracy of 94%, sensitivity of 98% and a specificity
of 80%. Thus, similar to our article EUS does have
a small amount of false negatives and may result in
unnecessary ERCP; two in our series and four in the
aforementioned study. It should be noted that the
ASGE and ESGE guidelines recommend an EUS or
MRCP for evaluation of patients with intermediate risk
of choledocholithiasis after a negative transabdominal
ultrasound, and not a CT scan.[4,5]
Transabdominal ultrasound is not sensitive for
choledocholithiasis with reports ranging from 22%
to 55%. [12] However, transabdominal ultrasound is
recommended for workup of choledocholithiasis
as it is a quick exam and it does detect bile duct
dilation in 77‑87% of the time. [12] EUS on the
other hand has reported sensitivities from 75% to
100% with sensitivities of 85%–100%.[6] For MRCP
the sensitivities range from 77% to 100% with
specificities from 73% to 99%. In a meta‑analysis of
5 head‑to‑head studies comparing EUS to MRCP for
choledocholithiasis, the pooled sensitivity of EUS was
97% and 90% respectively versus 87% and 92% for
MRCP respectively.[13] The diagnostic odds ratio was
higher for EUS versus MRCP (163 vs. 79; P = 0.008)
and was attributed to the higher sensitivity of EUS
versus MRCP (P = 0.006). The meta‑analysis concluded
that EUS should be in the diagnostic algorithm for
342

Table 3. Differences in demographic
characteristics, lab parameters, and clinical
parameters between magnetic resonance
cholangiopancreatography−/EUS+ and magnetic
resonance cholangiopancreatography−/EUS−
subgroups (n=124)
Demographic
characteristics
Age, mean (SD)
Sex
Female
Male
Lab parameters
WBC
<10.5×109/L
≥10.5×109/L
AST
≤40 U/L
>40 U/L
ALT
≤41 U/L
>41 U/L
Alkaline phosphatase
≤120 U/L
>120 U/L
Total bilirubin
≤3 mg/dL
>3 mg/dL
Clinical parameters
RUQ pain
No
Yes
Fever
No
Yes
Acute pancreatitis
No
Yes
Bacteremia
No
Yes

MRCP-/EUS+
(n=18), n (%)

MRCP-/EUS(n=106), n (%)

P

54.17 (16.71)

52.53 (18.47)

0.73

11 (61.11)
7 (38.89)

65 (61.32)
41 (38.68)

0.99

17 (94.44)
1 (5.56)

79 (74.53)
27 (25.47)

0.07

5 (27.78)
13 (72.22)

29 (27.36)
77 (72.64)

1.00

5 (27.78)
13 (72.22)

30 (28.30)
76 (71.70)

0.96

3 (16.67)
15 (83.33)

35 (33.02)
71 (66.98)

0.16

8 (44.44)
10 (55.56)

72 (67.92)
34 (32.08)

0.05

3 (16.67)
15 (83.33)

36 (33.96)
70 (66.04)

0.14

17 (94.44)
1 (5.56)

89 (83.96)
17 (16.04)

0.47

16 (88.89)
2 (11.11)

85 (80.19)
21 (19.81)

0.52

18 (100.00)
0 (0.00)

102 (96.23)
4 (3.77)

1.00

OR: Odds ratio; CI: Confidence interval; WBC: White blood cell count; AST:
Aspartate aminotransferase; ALT: Alanine aminotransferase; RUQ: Right
upper quadrant; SD: Standard deviation

choledocholithiasis when possible. However, MRCP is
less invasive, and does not require anesthesia. Thus, for
patients with comorbidities, it may be a better choice.
Overall, this study shows that patients who are
at inter mediate risk for choledocholithiasis that
undergo a negative MRCP may still be at risk for
choledocholithiasis. Thus, if the clinical suspicion
remains, an EUS exam may be warranted, especially
if the total bilirubin is above 3 mg/dL. In this study,
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Table 4. Univariable and multivariable association between covariates and “true positive” EUS for
choledocholithiasis among those no magnetic resonance cholangiopancreatography (n=328)
Variable

Univariable OR (95% CI)

Age
Sex (male vs. female)
WBC (≥10.5×109/L vs. <10.5×109/L)
AST (>40 U/L vs. ≤40 U/L)
ALT (>41 U/L vs. ≤41 U/L)
Alkaline phosphatase (>120 U/L vs. ≤120 U/L)
Total bilirubin (>3 mg/dL vs. ≤3 mg/dL)
RUQ pain (yes vs. no)
Fever (yes vs. no)
Acute pancreatitis (yes vs. no)
Bacteremia (yes vs. no)

1.01
0.73
1.29
3.27
3.77
3.85
2.31
2.73
1.28
0.55
1.50

(1.00–1.02)
(0.45–1.17)
(0.78–2.11)
(1.89–5.64)
(2.07–6.84)
(2.32–6.40)
(1.40–3.81)
(1.49–5.00)
(0.62–2.64)
(0.32–0.97)
(0.45–5.04)

P*

Multivariable OR (95% CI)

P

0.0928
0.1880
0.3181
<0.0001
<0.0001
<0.0001
0.0011
0.0011
0.5053
0.0387
0.5079

1.02 (1.00–1.03)
1.22 (0.48–3.10)
1.64 (0.64–4.21)
2.39 (1.28–4.47)
1.36 (0.76–2.42)
3.22 (1.62–6.37)
0.50 (0.27–0.93)
-

0.01
0.68
0.31
0.006
0.30
0.0008
0.03
-

*A P<0.10 was used as a cutoff for selection into the multivariable model. OR: Odds ratio; CI: Confidence interval; WBC: White blood cell count;
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; RUQ: Right upper quadrant

the MRCP exam missed a bile duct stone 14% of
the time compared to the gold standard ERCP. It is
important to note that our study is not showing a
superiority of EUS to MRCP, as such a study would be
designed differently. However, it does show that EUS
can be a useful tool to determine if MRCP missed
a stone. While a 14% diagnostic yield of EUS could
be considered moderate, it is important to note that
MRCP is considered a very sensitive test, and thus
one can argue that a 14% increased yield for diagnosis
of choledocholithiasis in an intermediate risk group is
significant. Moreover, 14% of undiagnosed bile duct
stones can lead to clinically significant illness caused by
acute pancreatitis or acute cholangitis in a population
with symptomatic choledocholithiasis.
We examined clinical and laboratory variables that
could be predictive of choledocholithiasis on both
EUS and subsequent ERCP. It was found that there
were no variables that predicted choledocholithiasis
in the negative MRCP group. When further analyzing
the MRCP negative group into MRCP−/EUS+ and
MRCP−/EUS− subgroups, a total bilirubin >3 mg/dL
predicted a bile duct stone. Generally, a total bilirubin
around 3 mg/dL does not predict bile duct stones,
and thus a high‑risk cohort for choledocholithiasis
is defined as 4 mg/dL or above. [4] However in
this subgroup of the study, a lower bilirubin was
statistically the cut off.
In the group that had no MRCP, the following
abnormal results predicted choledocholithiasis: RUQ
pain, abnor mal alkaline phosphatase, and acute
pancreatitis. This intuitively makes clinical sense, as
these patients would be considered to have a higher
suspicion for choledocholithiasis based on these

abnormal findings and thus would proceed directly to
EUS+/−ERCP.
In order to estimate the percentage of human error
in this study, all patients with negative MRCPs but
had “true positive” EUS had the MRCP re‑read by an
experienced GI radiologist. Two of these 21 negative
MRCPs were in fact positive on the re‑read. This shows
that interobserver variability does play a small role
in MRCP readings and should be taken into account
in clinical care. Perhaps all patients with negative
MRCPs that still have a high clinical suspicion for
choledocholithiasis should have the MRCP re‑reviewed
with a senior radiologist if available.
There are limitations to our study. First, this is a
retrospective study that can have its inherent associated
limitations. However, we attempted to mitigate this
with a re‑review of MRCP images from an experienced
radiologist. In addition, the gold standard for a
diagnosis of choledocholithiasis was an objective ERCP
finding of visible sludge or stones, not solely based on
the positive EUS interpretation that can be subjective.
It should be noted that it is possible that the stone
seen on EUS had migrated into the bile duct form
the gallbladder after the MRCP was performed; given
the EUS was performed after the MRCP and not at the
same time of the MRCP. However it should be noted
that these patients had continued pain and suspected
bile duct stones, so this is unlikely. Furthermore, of the
593 patients, 90 could not be evaluated for secondary
outcomes due to missing lab or clinical data. However,
this did not affect the primary outcome and thus we
feel does not hinder the study in a major way. Finally,
this study was conducted in a tertiary care center with
experienced endosonographers specifically trained in
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advanced endoscopy. Thus the results of this study are
limited to expert centers.

3.
4.

CONCLUSION
5.

We show that EUS can be a helpful tool that may
aid in the diagnosis of choledocholithiasis when an
MRCP is negative. The increased diagnostic yield
of EUS found in this study contributes to the data
from previous head-to-head studies showing the
superiority of EUS to MRCP for the diagnosis of
choledocholithiasis. Thus, EUS should be considered
the favored choice in the diagnostic algorithm for
choledocholithiasis if patients have limited comorbidities
and can tolerate anesthesia.
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